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Embryonic stem cells readily generate neurons in
vitro, but steering their differentiation into specific
neuronal subtypes is a major challenge. It has now
been shown that mechanisms that regulate neuronal
specification during development can be applied to
embryonic stem cells in vitro; this may lead to new
ways of generating cells for therapy.
Five centuries ago, Juan Ponce de Leon embarked on
his legendary quest for the mythic fountain of youth in a
newly discovered America. Needless to say, the trip was
a disaster, and he returned to Spain with bad news.
Modern day stem cell research seems to have uncov-
ered what eluded him for so long. Embryonic stem (ES)
cells are a cellular fountain of youth. Their remarkable
capacity to divide indefinitely in vitro without transfor-
mation, and their ability to generate all types of differen-
tiated progeny of the embryo, make ES cells
exceptionally well suited for the generation of spare cells
for the treatment of degenerative diseases. But just like
a fountain, their vigor needs to be harnessed — they can
readily form tumors or unwanted cell types.
ES cells can give rise to a large variety of cell types
in vitro, but appear to have a bias for certain lineages.
For example, they seldom give rise to endodermal cell
types. They do, however, very readily generate neural
cells, which appears to be a default differentiation
pathway [1]. It is therefore no mystery why so much
hope has lately been placed in ES cells as a source of
replacement neurons for patients with central nervous
system (CNS) injuries and diseases.
Neurodegenerative diseases, such as amyotrophic
lateral sclerosis (ALS) and Parkinson’s disease, are
characterized by the selective loss of certain classes of
neurons, and both have become major targets for the
development of stem-cell-based therapies. Clinical
trials, in which tissue containing dopamine neurons
from aborted human fetuses has been transplanted to
patients with Parkinson’s disease, have shown encour-
aging results, providing a proof of principle for cell
therapy in neurological diseases [2]. Fetal tissue,
however, is both hard to come by, and because con-
siderable amounts of tissue must be transplanted to
achieve results, it does not stretch very far.
An unlimited supply of neurons for transplantation
from stem cells would take this type of therapy a step
closer to a feasible clinical reality. But although ES
cells easily generate neurons in vitro, they do not
necessarily generate the types of neuron one would
wish, and finding ways to steer the differentiation of ES
cells into specific neuronal subtypes remains a major
challenge. Two new studies rise to this challenge,
describing methods to generate homogeneous popu-
lations of specific neurons from ES cells.
Wichterle et al. [3] have now reported exciting 
new findings with possible implications for ALS. The
generation of spinal cord neurons during nervous
system development is one of the best understood 
cellular differentiation events in embryogenesis [4].
Wichterle et al. [3] asked whether the signals that
direct neuronal specification during embryo-genesis
may be used to direct the generation of specific spinal
cord cell types from ES cells in vitro. They found 
that, once ES cells are neuralized, they behave almost 
identically to neural plate cells during normal 
embryonic development.
Wichterle et al. [3] first showed that, when ES cells 
are exposed to signals that impart a caudal character 
to neurons during embryogenesis, they start to express
markers of spinal cord progenitors. Then they used
Sonic hedgehog, a key morphogen for the establish-
ment of dorso-ventral patterning in the spinal cord [5], to
trick the cells into thinking that they are in the ventral
spinal cord, the home of spinal motor neurons. They
found that the ES cell-derived cells responded in a strik-
ingly similar way to endogenous spinal cord progenitors,
and that by modulating Sonic hedgehog signaling, it is
possible generate the major classes of spinal cord
neurons, including motor neurons, from ES cells. 
To characterize the properties of ES-cell-derived
motor neurons, Wichterle et al. [3] transplanted these
cells into the developing chick spinal cord and showed
that they integrate into the ventral horns, send axons
along appropriate pathways and make synapses with
muscle. Thus, by taking advantage of the knowledge of
how the embryonic nervous system is patterned, the
authors have found a way to recapitulate in vitro the
cues that naturally instruct spinal cord neurons during
development and, in doing so, to instruct ES cells to
form what looks like perfect motor neurons.
In another recent study, McKay and colleagues [6]
used a similar approach of mimicking developmental
cues to drive ES cells efficiently to form dopamine
neurons, the cells affected in Parkinson’s disease.
Several key steps in the generation of dopaminergic
midbrain neurons during development have been
characterized [7]. In a series of studies, McKay and
colleagues [8,9] have developed increasingly more
refined protocols for the generation of dopaminergic
neurons from both fetal neural stem cells and ES cells.
They have previously shown that Sonic hedgehog and
fibroblast growth factor 8 (FGF8) — signals which act
to induce the generation of dopaminergic midbrain
neurons during development — efficiently promote the
generation of these neurons from ES cells. 
Now, by expressing in ES cells the orphan nuclear
hormone receptor Nurr1, critically required for the
differentiation of dopamine midbrain neurons in vivo
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[10], Kim et al. [6] have developed a protocol which
produces a very highly enriched culture of dop-
amine neurons. These neurons have electrophysio-
logical properties and a marker profile associated with
their in vivo counterparts. The authors went on to
transplant these cells to the striatum of animals in
which a Parkinson-like lesion had been induced 
by selectively killing the midbrain dopamine neurons.
The idea was that these transplanted neurons might
integrate into the striatum and release dopamine,
thereby replacing the lost input from the midbrain
dopamine neurons.
The experimental animals showed a remarkable
recovery effect in behavioral tests [6]. It even appears
as though the loss of neurons is overcompensated, as
the animals showed signs of higher than normal
dopamine release. This finding cautions that the
number of cells that are transplanted needs to be care-
fully titrated, and it may be advantageous to incorpo-
rate methods that enable the elimination of excess
transplanted cells if the effect were to be too strong.
Together with recent papers [11,12] showing hema-
topoietic reconstitution with ES cell-derived cells, the
McKay group’s new study [6] illustrates the increasing
potential of ES cells in therapeutic situations.
These new studies [3,6] have shown that specific
subclasses of neurons can be efficiently generated
from ES cells in vitro, and the simplicity of the
methods is surprising indeed. Cells cultured in vitro
are often considered to be very different from their 
in vivo counterparts, for even our best efforts at 
creating complex conditions in vitro are often thought
to fall far short of reproducing a natural in vivo
environment. It is therefore astonishing that a precious
few factors can allow us to mimic in a dish a pro-
foundly complex developmental program that occurs
during embryogenesis.
Many in vitro conditions have been established to
promote the differentiation of certain types of cell from
ES cells. They have most often been developed by the
careful and meticulous testing of different factors and
culture conditions rather than by the use of informa-
tion garnered from development. The success of
these new studies teaches us that the best insight into
how to harness the fountain of youth may be to adopt
the strategies developed by nature to direct cellular
differentiation during embryogenesis.
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